Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Christopher R. Fenimore is EVP Finance CFO at Regeneron Pharmaceuticals. OQRO lists 10 transactions filed with the SEC under this name, the latest on Nov 4, 2026, each linked to the official Form 4.
EVP Finance CFO
Disclosures on record
10
Companies involved
1
Regeneron PharmaceuticalsREGN
10 disclosures · Dec 2025 – Nov 2026
Nov 2, 20266,000disclosed Nov 4
DetailsOfficial recordNov 2, 20266,000disclosed Nov 4
DetailsOfficial recordAs of the latest filing on , Christopher R. Fenimore reported holding 21,726 shares of Regeneron Pharmaceuticals (REGN), worth about $20M at the last close of $921 (Nov 20, 2026).
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Regeneron Pharmaceuticals REGN | 21,726 | 22K direct | $921 | $20M | Nov 2, 2026 |
Is this Christopher R. Fenimore’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Nov 2, 202615disclosed Nov 4
DetailsOfficial recordNov 2, 20264,243disclosed Nov 4
DetailsOfficial recordAug 18, 20266,283disclosed Aug 20
DetailsOfficial recordAug 18, 20266,283disclosed Aug 20
DetailsOfficial recordAug 18, 20264,599disclosed Aug 20
DetailsOfficial recordDec 5, 20253,027disclosed Dec 9
DetailsOfficial recordDec 5, 202515Kdisclosed Dec 9
DetailsOfficial recordDec 8, 2025992disclosed Dec 9
DetailsOfficial recordChristopher R. Fenimore has no open-market purchase on record since 2018. Sales in 7 of the 9 years since 2018.
Christopher R. Fenimore reported 0 open-market purchases and 84 sales since 2018; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2024 | — | $11.5M16×16 trades |
| 2023 | — | $5.49M5×5 trades |
| 2022 | — | $3.8M2×2 trades |
| 2021 | — | $3.13M7×7 trades |
| 2020 | — | $5.07M41×41 trades |
| 2019 | — | $633K5×5 trades |
| 2018 | — | $663K8×8 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Nov 2, 2026, Christopher R. Fenimore reported holding 21,726 shares of Regeneron Pharmaceuticals (REGN). At the last close of $921 on Nov 20, 2026, that is about $20M. This is the stake disclosed in filings, not a net worth.
No public filing gives Christopher R. Fenimore's net worth. What SEC Form 4 shows is the stock stake: 21,726 shares of Regeneron Pharmaceuticals (REGN), about $20M at the last close. Cash, other investments, property, debts and unexercised options are not in these filings, so the real figure can be much higher or lower.
Christopher R. Fenimore has no open-market purchase on record since 2018. Sales in 7 of the 9 years since 2018.
In SEC filings since 2018: no open-market purchase is on record; the latest open-market sale is from 2024.
Regeneron Pharmaceuticals (REGN), from 2018 to 2024: 0 purchases and 84 sales.
Christopher R. Fenimore reported 0 open-market purchases and 84 sales here, 2018 to 2024.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.